BNP Paribas Financial Markets Makes New $2.03 Million Investment in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

BNP Paribas Financial Markets acquired a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 58,857 shares of the company's stock, valued at approximately $2,025,000. BNP Paribas Financial Markets owned about 0.10% of Harmony Biosciences as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of HRMY. Vanguard Group Inc. raised its position in shares of Harmony Biosciences by 36.4% in the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after purchasing an additional 1,262,362 shares during the last quarter. Marshall Wace LLP lifted its position in Harmony Biosciences by 165.2% during the 4th quarter. Marshall Wace LLP now owns 929,744 shares of the company's stock worth $31,992,000 after acquiring an additional 579,103 shares during the period. Norges Bank acquired a new stake in Harmony Biosciences during the 4th quarter worth about $16,118,000. Pacer Advisors Inc. lifted its position in Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock worth $78,452,000 after acquiring an additional 351,582 shares during the period. Finally, Invesco Ltd. lifted its position in Harmony Biosciences by 173.9% during the 4th quarter. Invesco Ltd. now owns 449,180 shares of the company's stock worth $15,456,000 after acquiring an additional 285,156 shares during the period. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Price Performance

Shares of Harmony Biosciences stock traded up $0.04 on Friday, hitting $34.17. The company's stock had a trading volume of 392,819 shares, compared to its average volume of 600,606. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a 1 year low of $26.47 and a 1 year high of $41.61. The firm has a fifty day moving average price of $31.58 and a 200-day moving average price of $34.02. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of 16.19, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $184.73 million during the quarter, compared to analyst estimates of $184.26 million. During the same quarter in the previous year, the business earned $0.67 EPS. Harmony Biosciences's revenue for the quarter was up 19.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HRMY has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Needham & Company LLC reissued a "buy" rating and issued a $49.00 price objective on shares of Harmony Biosciences in a report on Tuesday, May 6th. UBS Group decreased their price objective on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a report on Monday, April 28th. Finally, Cantor Fitzgerald raised Harmony Biosciences to a "strong-buy" rating in a report on Tuesday, May 13th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $52.78.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.